How to Start a TRT Business: Clinical, Legal, and Operational Requirements

If you want to start a TRT business, build it as a clinician-led, state-aware healthcare operation—not a subscription commerce brand. The essential work includes licensed clinical oversight, documented evaluation and lab review, controlled-substance compliance, HIPAA-conscious technology, transparent recurring billing, substantiated marketing, and state-by-state review before patients are accepted.

What does a TRT business model include?

A testosterone clinic business model can combine clinical care with technology, administrative support, laboratory coordination, pharmacy relationships, and recurring payments. Those functions should be planned separately so commercial operations do not direct clinical decisions.

Common structures include:

• Direct-to-consumer telehealth practice: Licensed clinicians evaluate patients located in jurisdictions where they are authorized to practice.
• Hybrid clinic: Telehealth is combined with in-person services, specimen collection, or follow-up.
• Membership or subscription model: Patients pay recurring fees for clearly defined administrative or clinical services, subject to transparent billing and cancellation terms.
• Referral or coordination model: A business supports intake, scheduling, or operations while licensed clinicians retain clinical authority.

MDLaunchr is one platform in the white-label telehealth infrastructure category. Its role is to help qualified businesses evaluate and coordinate technology, operational, compliance, clinical-network, and fulfillment relationships; it does not replace licensure, a treating clinician, or legal review.

Founders comparing a virtual or hybrid model can also review why specialty practices are adding direct-to-consumer telehealth.

What are the core requirements for starting a TRT business?

A launch plan should account for seven connected workstreams:

The business should document ownership, accountability, escalation, and audit processes for each workstream rather than treating compliance as a final website review.

Is testosterone a controlled substance?

Yes. DEA materials identify testosterone and anabolic steroids as Schedule III controlled substances. A TRT business therefore needs controlled-substance procedures in addition to ordinary telehealth operations.

At a minimum, the operating plan should include:

1. 1Verification that each prescribing clinician has the required DEA registration and state authority.
2. 2Records supporting a legitimate medical purpose for prescribing.
3. 3Controlled-substance recordkeeping and audit procedures in the EHR and compliance program.
4. 4Separation between clinical decisions and subscription, refill, conversion, or revenue metrics.
5. 5A process for reviewing changes in federal and state requirements.

As of October 8, 2026, DEA and HHS have extended current federal telemedicine flexibilities for prescribing Schedule II–V controlled substances through December 31, 2026. That is a temporary federal extension. It does not eliminate state requirements or guarantee that a particular online TRT model is lawful in every state.

Can an online TRT practice prescribe through telehealth?

It may be possible under applicable federal and state rules, but the answer depends on the patient’s location, the clinician’s authority, the prescribing circumstances, and the current telemedicine requirements. A website’s national reach does not create authority to treat patients everywhere.

For each encounter, build a workflow to:

• Confirm the patient’s physical location.
• Verify patient identity.
• Confirm the clinician’s licensure and authorization for that jurisdiction.
• Record the encounter, assessment, available laboratory information, and follow-up plan.
• Use technology with appropriate privacy and security controls.
• Escalate patients who need in-person evaluation or specialty care.

HHS states that covered providers may conduct telehealth using remote communications technology when HIPAA requirements and reasonable safeguards are met. Providers should ordinarily conduct telehealth in private settings. HHS guidance does not create a nationwide substitute for state professional licensure, so state medical-board and pharmacy-board review remains necessary.

How should a TRT clinic design its lab workflow?

The lab workflow should be designed as a clinical quality system, not as an automated eligibility quiz. Federal sources do not establish one universal testing schedule or protocol, so the treating clinician must determine appropriate evaluation and follow-up within applicable standards of care.

Use this operational sequence:

1. 1Collect intake information and verify identity.
2. 2Arrange appropriate laboratory information through legally permitted channels.
3. 3Have a qualified clinician review and interpret the information.
4. 4Document the clinical decision and the information supporting it.
5. 5Notify the patient through the approved communication workflow.
6. 6Define follow-up and reassessment responsibilities.
7. 7Escalate abnormal, incomplete, stale, or conflicting information.
8. 8Retain records according to the practice’s documented policy and applicable requirements.

Before contracting with a laboratory or technology vendor, decide who orders tests, who reviews results, how duplicate or outdated results are handled, and what happens when findings require in-person care. Do not present a questionnaire, automated score, or software rule as a substitute for clinician evaluation.

What should founders know about pharmacy and compounding relationships?

A pharmacy relationship requires separate diligence, especially if the model involves compounded products. FDA distinguishes between Section 503A pharmacy compounding and Section 503B outsourcing-facility compounding. Section 503A generally concerns patient-specific compounding by a licensed pharmacist or physician under statutory conditions; Section 503B concerns registered outsourcing facilities.

FDA also warns that people using online pharmacies or telehealth platforms may not know the identity of the compounder or whether it is appropriately licensed and regulated. Before launch:

• Verify the pharmacy’s licensing and regulatory status.
• Document the legal relationship among the practice, prescriber, pharmacy, and patient.
• Clarify which entity selects and supervises the pharmacy relationship.
• Obtain specialized legal and pharmacy-regulatory review.
• Avoid suggesting that compounded products are automatically equivalent to FDA-approved products.

A fulfillment relationship should never be treated as a generic logistics vendor relationship. For additional diligence questions, see how to choose a telehealth compounding pharmacy.

What state rules must a hormone therapy business review?

A national hormone therapy brand still needs a state-by-state operating plan. The relevant rules can differ based on where the patient is located and how the clinical entity, management company, laboratory, pharmacy, and clinicians are structured.

Review the following for every intended service state:

• Professional licensure and telehealth practice authority.
• Full, provisional, compact, or special-purpose licensure options.
• Telehealth consent and documentation requirements.
• Any in-person examination requirement for the intended prescribing model.
• State controlled-substance prescribing and monitoring rules.
• Prescription-drug-monitoring-program obligations.
• Corporate-practice-of-medicine and medical-practice ownership restrictions.
• Medical-director and supervision requirements.
• Fee-splitting and management-services limitations.
• Pharmacy and nonresident-pharmacy licensing.
• Prescription-drug shipment rules.
• Clinical-laboratory and specimen-collection requirements.
• State privacy, consumer-protection, and automatic-renewal rules.
• Membership, refund, and cancellation disclosures.
• Rules affecting nurse practitioners, physician assistants, and other clinicians.

The federal research available for this article does not resolve state-specific questions. Founders should verify requirements with the relevant medical, pharmacy, nursing or physician-assistant, attorney general, health, and business-licensing authorities, as appropriate, and obtain qualified legal advice.

What technology and privacy controls are needed?

The technology stack should be evaluated as a connected system, not selected from a single feature list. Potential vendors include the EHR and patient portal, video platform, intake forms, lab interfaces, payment system, customer-support tools, analytics and advertising technologies, cloud storage, and pharmacy or fulfillment integrations.

HHS explains that HIPAA applies to covered entities and business associates. A vendor handling protected health information for billing, claims processing, practice management, data analysis, or similar functions may qualify as a business associate, and a written business associate agreement may be required.

HIPAA is not the only privacy consideration. HHS notes that the FTC Act and Health Breach Notification Rule may apply to businesses collecting or sharing consumer health information, including businesses that are not HIPAA-covered entities. Review data flows before deploying analytics, advertising pixels, messaging tools, or support software.

How should recurring billing work?

Recurring billing should clearly explain what the customer is buying, when charges occur, how renewals work, and how cancellation takes effect. A membership or subscription cannot be treated as merely a marketing feature.

Before accepting payment, document and test this workflow:

1. 1Display the recurring price and billing frequency.
2. 2Explain what the recurring charge covers.
3. 3Separate consultation, membership, laboratory, and medication charges where applicable.
4. 4State when the first charge occurs and when future renewals occur.
5. 5Obtain affirmative consent to recurring charges.
6. 6Provide a simple cancellation method.
7. 7Confirm cancellation promptly.
8. 8Record disclosures, consent, billing events, refunds, and cancellation requests.
9. 9Avoid charging before the consumer understands whether a clinician has evaluated the request, where that distinction is material.

A July 2026 FTC enforcement action involving Hims & Hers alleged that consumers were enrolled in recurring treatment subscriptions without sufficiently clear consent and faced difficulty understanding refill timing and cancellation. That action is a useful reminder to test the actual customer journey, not only the written terms. HIPAA may permit certain uses of information for payment, but HIPAA permission does not make a billing practice lawful under consumer-protection rules.

What marketing claims can a hormone therapy business make?

Health-related advertising must be truthful, not misleading, and supported by competent and reliable scientific evidence. Claims involving energy, aging, body composition, sexual function, disease prevention, or broad “optimization” may require careful substantiation.

Create an approval process for website copy, advertisements, clinician testimonials, patient reviews, influencer content, and before-and-after materials. Avoid claims promising or implying:

• Guaranteed hormone changes or outcomes.
• Guaranteed weight loss or muscle gain.
• Anti-aging results.
• Prevention of serious diseases.
• Universal patient suitability.
• Risk-free or instant results.
• “Clinically proven” results without appropriate evidence.
• Regulatory approval that does not exist.

Marketing should describe the service accurately—for example, clinician-led evaluation, documented follow-up, or coordinated operational support—without turning those descriptions into outcome promises.

What is the right launch sequence?

Use this order to reduce rework:

1. Define the clinical model

Decide whether the service is virtual, hybrid, referral-based, membership-based, cash-pay, insurance-related, or a combination. Identify who owns clinical decisions.

2. Map the service states

List the states where patients may be located and assign responsibility for verifying licensure, telehealth, controlled-substance, pharmacy, laboratory, ownership, and consumer-protection requirements.

3. Build the clinical and lab workflow

Define intake, identity verification, evaluation, laboratory information, clinician review, documentation, follow-up, escalation, and referral processes.

4. Vet relationships and technology

Review clinicians, laboratories, pharmacies, EHR and telehealth vendors, payment systems, support tools, and data-sharing practices. Determine where business associate agreements may be required.

5. Write billing and marketing controls

Approve pricing disclosures, recurring consent, cancellation, refund, complaint, advertising, testimonial, and evidence-review procedures.

6. Test before enrollment

Run sample journeys for a new patient, an incomplete laboratory record, an abnormal finding, a patient in another state, a cancellation request, a failed payment, and a need for in-person referral.

7. Launch with monitoring

Track licensure expirations, DEA requirements, privacy reviews, complaints, billing events, marketing approvals, and clinical-operational boundaries.

WhiteLabelClinic.com is designed to help qualified businesses coordinate the infrastructure relationships involved in this process. It is not a medical practice, regulator, pharmacy, or guarantee that a proposed model will be approved.

Pre-launch checklist

• Define the clinical entity and any nonclinical management entity.
• Identify every state in which patients may be located.
• Verify clinician licensure, scope, and telehealth authority.
• Confirm applicable DEA registration and state controlled-substance requirements.
• Decide whether the practice orders outside testing, collects specimens, or performs testing.
• Document the laboratory review and abnormal-result escalation workflow.
• Vet any pharmacy or compounding relationship and its regulatory status.
• Inventory every vendor that may handle protected health information.
• Determine which vendors require business associate agreements.
• Explain recurring charges, renewal timing, refunds, and cancellation before payment.
• Test cancellation and confirmation procedures.
• Review health claims, testimonials, influencer content, and evidence.
• Separate clinical decisions from conversion, refill, and subscription metrics.
• Establish complaint, audit, documentation, and escalation procedures.

Is compounded hormone therapy automatically FDA-approved?

No. FDA distinguishes 503A pharmacy compounding from 503B outsourcing-facility compounding, and compounded products should not be marketed as automatically equivalent to FDA-approved products. Pharmacy licensing, regulatory status, and the practice-pharmacy relationship require separate diligence.

Can I launch nationally with one set of rules?

No. A national website still needs state-specific review because licensure, telehealth, controlled-substance, ownership, pharmacy, laboratory, privacy, and consumer-protection requirements can differ by jurisdiction.

Bottom line

Starting a TRT business means designing a regulated clinical-service operation around licensed clinicians, controlled-substance controls, state authority, documented laboratory review, privacy safeguards, transparent billing, and substantiated marketing. Build those systems before scaling the brand or enrollment funnel.

Explore how MDLaunchr and WhiteLabelClinic.com can support a compliance-first telehealth launch.

Related reading: the full guide this article belongs to.